BRIACELL THERAPEUTICS CORP (BCTX) Stock Price & Overview
NASDAQ:BCTX • CA1079303071
Current stock price
The current stock price of BCTX is 4.43 USD. Today BCTX is up by 2.55%. In the past month the price decreased by -1.99%. In the past year, price decreased by -98.97%.
BCTX Key Statistics
- Market Cap
- 32.118M
- P/E
- N/A
- Fwd P/E
- N/A
- EPS (TTM)
- -128.19
- Dividend Yield
- N/A
BCTX Stock Performance
BCTX Stock Chart
BCTX Technical Analysis
ChartMill assigns a technical rating of 2 / 10 to BCTX. When comparing the yearly performance of all stocks, BCTX is a bad performer in the overall market: 94.96% of all stocks are doing better.
BCTX Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to BCTX. No worries on liquidiy or solvency for BCTX as it has an excellent financial health rating, but there are worries on the profitability.
BCTX Earnings
BCTX Forecast & Estimates
BCTX Groups
Sector & Classification
BCTX Financial Highlights
Over the last trailing twelve months BCTX reported a non-GAAP Earnings per Share(EPS) of -128.19. The EPS decreased by -184.87% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -88.22% | ||
| ROE | -95.86% | ||
| Debt/Equity | 0 |
BCTX Ownership
BCTX Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 14.05 | 369.653B | ||
| AMGN | AMGEN INC | 15.56 | 188.346B | ||
| GILD | GILEAD SCIENCES INC | 15.57 | 171.971B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 22.65 | 110.812B | ||
| REGN | REGENERON PHARMACEUTICALS | 16.01 | 78.867B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 45.37 | 42.456B | ||
| INSM | INSMED INC | N/A | 30.821B | ||
| RVMD | REVOLUTION MEDICINES INC | N/A | 29.581B | ||
| NTRA | NATERA INC | N/A | 27.795B | ||
| BIIB | BIOGEN INC | 11 | 25.833B | ||
| UTHR | UNITED THERAPEUTICS CORP | 20.13 | 25.444B | ||
| MRNA | MODERNA INC | N/A | 21.686B | ||
| INCY | INCYTE CORP | 12.64 | 18.97B |
Related stock screener links
View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About BCTX
Company Profile
BriaCell Therapeutics Corp. is a clinical-stage biotechnology company, which engages in the development of novel immunotherapies to transform cancer care. The company is headquartered in West Vancouver, British Columbia and currently employs 20 full-time employees. The company went IPO on 2006-10-12. Bria-IMT, its Phase 3 lead candidate, is a patented, off-the-shelf, cell-based, targeted immunotherapy that activates the patient’s immune system to specifically kill cancer cells without harming other cells. The firm is advancing its Bria-IMT targeted immunotherapy in combination with an immune check point inhibitor (Retifanlimab) in a pivotal Phase 3 study in metastatic breast cancer. The company is also developing personalized off-the-shelf immunotherapies, Bria-OTS and Bria-OTS+, which provides a platform technology to develop personalized off-the-shelf immunotherapies for numerous types of cancer, and a soluble CD80 protein therapeutic which act both as a stimulator of the immune system, as well as an immune checkpoint inhibitor. Its pipeline also includes Bria-IMT + CPI, Bria-BRES/BRES+, Bria-PROS+, Bria-LUNG+ and Bria-MEL+.
Company Info
IPO: 2006-10-12
BRIACELL THERAPEUTICS CORP
Suite 300 - Bellevue Centre, 235 -15th Street
West Vancouver BRITISH COLUMBIA V7T 2X1 CA
CEO: William V. Williams
Employees: 20
Phone: 16049211810
BRIACELL THERAPEUTICS CORP / BCTX FAQ
What does BRIACELL THERAPEUTICS CORP do?
BriaCell Therapeutics Corp. is a clinical-stage biotechnology company, which engages in the development of novel immunotherapies to transform cancer care. The company is headquartered in West Vancouver, British Columbia and currently employs 20 full-time employees. The company went IPO on 2006-10-12. Bria-IMT, its Phase 3 lead candidate, is a patented, off-the-shelf, cell-based, targeted immunotherapy that activates the patient’s immune system to specifically kill cancer cells without harming other cells. The firm is advancing its Bria-IMT targeted immunotherapy in combination with an immune check point inhibitor (Retifanlimab) in a pivotal Phase 3 study in metastatic breast cancer. The company is also developing personalized off-the-shelf immunotherapies, Bria-OTS and Bria-OTS+, which provides a platform technology to develop personalized off-the-shelf immunotherapies for numerous types of cancer, and a soluble CD80 protein therapeutic which act both as a stimulator of the immune system, as well as an immune checkpoint inhibitor. Its pipeline also includes Bria-IMT + CPI, Bria-BRES/BRES+, Bria-PROS+, Bria-LUNG+ and Bria-MEL+.
What is the stock price of BRIACELL THERAPEUTICS CORP today?
The current stock price of BCTX is 4.43 USD. The price increased by 2.55% in the last trading session.
Does BRIACELL THERAPEUTICS CORP pay dividends?
BCTX does not pay a dividend.
What is the ChartMill technical and fundamental rating of BCTX stock?
BCTX has a ChartMill Technical rating of 2 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
Can you provide the PE ratio for BCTX stock?
BRIACELL THERAPEUTICS CORP (BCTX) does not have a PE ratio as the earnings reported over the last twelve months were negative (-128.19).
What is the Short Interest ratio of BRIACELL THERAPEUTICS CORP (BCTX) stock?
The outstanding short interest for BRIACELL THERAPEUTICS CORP (BCTX) is 3.91% of its float.